Seeking Alpha

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC ...
Nasdaq

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all patients expected in first half of 2025 Full enrollment in LOTIS-5 ...
Seeking Alpha

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Initial MZL IIT Phase 2 data from 15 patients showed 13 patients with CR and 1 patient with PR; encouraging data compared to current treatments in area with high unmet medical need Research event ...
Hosted on MSN

ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript

ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, expectations were $-0.35. Operator: Good ...
Nasdaq

ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the ...